As the United States continues to fight the coronavirus pandemic, it may soon have a new source of hope: a fourth vaccine. An AstraZeneca executive told CBS News on Friday that the company plans to file an emergency use authorization application for its vaccine in the coming weeks, pending the results of a clinical trial.
Ruud Dobber, executive vice president of AstraZeneca, told CBSN presenter Tanya Rivero on Friday that the drugmaker hopes to receive the results of its clinical trial “in the coming weeks.” He then immediately foreseesfor his two-dose vaccine from the Food and Drug Administration, he said. If cleared, he said AstraZeneca is ready to deliver tens of millions of doses to the United States.
“In the first months after the [authorization], we plan to instantly deliver about 50 million doses to Americans, ”Dobber said.
In addition to the Oxford-AstraZeneca vaccine, three other vaccines have already been approved for use in the United States:and , which are both two doses, and , which only requires one dose.
The AstraZeneca vaccine is already being administered internationally, having received the green light from the European Union, the United Kingdom and the World Health Organization in recent months.
Dobber said AstraZeneca’s current vaccine may prove effective against at least one of the disease’s emerging mutations.
“We are optimistic that he is very effective against the British variant,” he said.
The company is already “developing a potential new vaccine in case our current vaccine isn’t as effective as we hoped,” Dobber said.